Literature DB >> 1702345

Surgical management of pericardial effusion in patients with malignancies. Comparison of subxiphoid window versus pericardiectomy.

J S Park1, R Rentschler, D Wilbur.   

Abstract

There is a lack of consensus regarding optimal surgical management of symptomatic pericardial effusions in patients with malignancies. Subxiphoid pericardial window formation (subxiphoid pericardial drainage) has been considered a safe and effective method for diagnostic and therapeutic purposes. To ensure adequate drainage, many surgeons prefer the formation of a larger pericardial window by performing either an anterior thoracotomy or a partial/total pericardiectomy. To evaluate the efficacy of these methods for palliation of symptomatic pericardial effusion in patients with malignancy, 28 consecutive pericardial surgery cases involving patients with malignancy were retrospectively analyzed. Ten patients (Group 1) had subxiphoid window formation, whereas 18 patients (Group 2) had partial or total pericardiectomy or pericardial window formation by anterior thoracotomy. There was no statistically significant difference (P = 0.22) in the survival rates between these two groups. A median survival time of 2.67 months (range, 0.43 to 26.6 months) was observed in Group 1 versus 1.23 months (range, 0.03 to 10.83 months) in Group 2. However, a statistically significant difference (P less than or equal to 0.02) in postoperative morbidity was observed between the two groups: 67% in Group 2 versus 10% in Group 1. Because of lower morbidity, subxiphoid pericardial window formation is recommended by this study as the preferred surgical method for palliation of symptomatic pericardial effusion in patients with malignancy.

Entities:  

Mesh:

Year:  1991        PMID: 1702345     DOI: 10.1002/1097-0142(19910101)67:1<76::aid-cncr2820670115>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Occult cardiac lymphoma presenting with cardiac tamponade.

Authors:  Douglas B Wilhite; Robert L Quigley
Journal:  Tex Heart Inst J       Date:  2003

2.  Pericardial effusion in patients with cancer: outcome with contemporary management strategies.

Authors:  R J Laham; D J Cohen; R E Kuntz; D S Baim; B H Lorell; M Simons
Journal:  Heart       Date:  1996-01       Impact factor: 5.994

3.  Successful treatment of malignant pericardial effusion, using weekly paclitaxel, in a patient with breast cancer.

Authors:  Takahiro Einama; Kazuhiko Sato; Hitoshi Tsuda; Hidetaka Mochizuki
Journal:  Int J Clin Oncol       Date:  2006-10       Impact factor: 3.402

4.  Percutaneous treatment in patients presenting with malignant cardiac tamponade.

Authors:  P Y Marcy; P Y Bondiau; P Brunner
Journal:  Eur Radiol       Date:  2005-01-21       Impact factor: 5.315

5.  Clinical experience with pericardiocentesis and extended drainage in a population with a high prevalence of HIV.

Authors:  V J Louw; H Reuter; J P Smedema; I Katjitae; L J Burgess; A F Doubell
Journal:  Neth Heart J       Date:  2002-10       Impact factor: 2.380

6.  Long-Term Outcomes after Video-Assisted Thoracoscopic Pericardiectomy for Pericardial Effusion.

Authors:  Yasushi Mizukami; Nobuhito Ueda; Hirofumi Adachi; Jun Arikura; Keishi Kondo
Journal:  Ann Thorac Cardiovasc Surg       Date:  2017-08-09       Impact factor: 1.520

7.  Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients.

Authors:  Kan Yonemori; Hideo Kunitoh; Koji Tsuta; Tetsutaro Tamura; Yasuaki Arai; Yasuhiro Shimada; Yasuhiro Fujiwara; Yuko Sasajima; Hisao Asamura; Tomohide Tamura
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

8.  Percutaneous balloon pericardiotomy in the management of recurrent malignant pericardial effusions.

Authors:  G Jackson; D Keane; B Mishra
Journal:  Br Heart J       Date:  1992-12

9.  Performance, pain, and quality of life on use of central venous catheter for management of pericardial effusions in patients undergoing coronary artery bypass graft surgery.

Authors:  Kamran Ghods; Mohammad Reza Razavi; Mohammad Forozeshfard
Journal:  J Pain Res       Date:  2016-10-31       Impact factor: 3.133

10.  A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811).

Authors:  H Kunitoh; T Tamura; T Shibata; M Imai; Y Nishiwaki; M Nishio; A Yokoyama; K Watanabe; K Noda; N Saijo
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.